Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome-Reference-Cited by-同舟云学术

Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Relapsing Post-Adjuvant Trastuzumab: Pattern of Recurrence, Treatment and Outcome

Published:2011-06 Issue:3 Volume:11 Page:153-160
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Krell Jonathan,James Colin R.,Shah Deep,Gojis Ondrej,Lim Adrian,Riddle Pippa,Ahmad Riz,Makris Andreas,Cowdray Andrew,Chow Angela,Babayev Tamerlan,Madden Peter,Leonard Robert,Cleator Susan,Palmieri Carlo

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference27 articles.

1. Prognostic markers in breast cancer: the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer;Taucher;Wien Klin Wochenschr,2004

2. Discordance between core needle biopsy (CNB) and excisional biopsy (EB) for estrogen receptor (ER), progesterone receptor (PgR) and HER2 status in early breast cancer (EBC);Arnedos;Ann Oncol,2009

3. Human breast cancer: correlation of relapse and survival with amplification of the HER2-2/neu oncogene;Slamon;Science,1987

4. ERBB2 oncogene in human breast cancer and its clinical significance;Revillion;Eur J Cancer,1998

5. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization;Kallioniemi;Proc Natl Acad Sci USA,1992

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DiffRS-net: A Novel Framework for Classifying Breast Cancer Subtypes on Multi-Omics Data;Applied Sciences;2024-03-25

2. Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study;ESMO Open;2020

3. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial;ESMO Open;2020

4. Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study;Breast Cancer: Basic and Clinical Research;2018-01-01

5. Survival outcomes for Australian women receiving trastuzumab for HER2-positive metastatic breast cancer following (neo)adjuvant trastuzumab: a national population-based observational study (2006–2014);British Journal of Cancer;2017-11-14